Clinical Trial Update: A Safety and Tolerability Study of Denufosol in 2-4 Year Olds [Phase 2]

View source ↗

Summary

A phase 2 safety and tolerability study of denufosol in 2- to 4-year-old children with cystic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Denufosol

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED